前列腺癌新分级分组预后价值:一项多机构欧洲验证研究
该研究分析欧洲七中心27122例根治性前列腺切除术患者,评估活检和术后标本新分级分组(基于Gleason评分3+3、3+4、4+3、8、9-10)对生化复发的独立预后价值。中位随访29个月,新分级分组与生化复发独立相关,但未在临床显著程度上改善预后模型准确性。
要点
- 活检和术后标本新分级分组均与生化复发独立相关(所有P<0.01)。
- 术后标本仅分级分组3与4之间差异未达统计学显著(P=0.10)。
- 新五级分类未在临床显著程度上提升预后模型区分度。
核心结论
- 新分级分组在活检和术后标本中均具有独立预后价值,但未在临床显著程度上改善预后模型准确性。
研究设计与样本
- 多机构欧洲验证研究,纳入七中心27122例接受根治性前列腺切除术的前列腺癌患者。
主要发现
- 中位随访29个月(四分位距13-54)。
- 活检分级分组1-5的4年估计无生化复发生存率分别为91.3%、81.6%、69.8%、60.3%和44.4%。
- 术后标本分级分组1-5的4年估计无生化复发生存率分别为96.1%、86.7%、67.0%、63.1%和41.0%。
- 与分级分组1相比,活检和术后标本的其他所有分级分组均与较低无生化复发生存率独立相关(所有P<0.01)。
- 校正后两两比较显示所有分级分组间均有统计学差异,但术后标本分级分组3与4之间除外(P=0.10);临床和病理模型的区分度分别提高0.3%和0.9%。
临床怎么用
- 作者认为,这一新分类可能帮助医生和患者以用户友好、临床相关且可重复的方法估计疾病侵袭性。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: We aimed to assess the prognostic relevance of the new Grade Groups in Prostate Cancer (PCa) within a large cohort of European men treated with radical prostatectomy (RP). METHODS: Data from 27 122 patients treated with RP at seven European centers were analyzed. We investigated the prognostic performance of the new Grade Groups (based on Gleason score 3+3, 3+4, 4+3, 8 and 9-10) on biopsy and RP specimen, adjusted for established clinical and pathological characteristics. Multivariable Cox proportional hazards regression models assessed the association of new Grade Groups with biochemical recurrence (BCR). Prognostic accuracies of the models were assessed using Harrell's C-index. RESULTS: Median follow-up was 29 months (interquartile range, 13-54). The 4-year estimated BCR-free survival (bRFS) for biopsy Grade Groups 1-5 were 91.3, 81.6, 69.8, 60.3 and 44.4%, respectively. The 4-year estimated bRFS for RP Grade Groups 1-5 were 96.1%, 86.7%, 67.0%, 63.1% and 41.0%, respectively. Compared with Grade Group 1, all other Grade Groups based both on biopsy and RP specimen were independently associated with a lower bRFS (all P<0.01). Adjusted pairwise comparisons revealed statistically differences between all Grade Groups, except for group 3 and 4 on RP specimen (P=0.10). The discriminations of the multivariable base prognostic models based on the current three-tier and the new five-tier systems were not clinically different (0.3 and 0.9% increase in discrimination for clinical and pathological model). CONCLUSIONS: We validated the independent prognostic value of the new Grade Groups on biopsy and RP specimen from European PCa men. However, it does not improve the accuracies of prognostic models by a clinically significant margin. Nevertheless, this new classification may help physicians and patients estimate disease aggressiveness with a user-friendly, clinically relevant and reproducible method.
引用
- Mathieu R, Moschini M, Beyer B, et al. Prognostic value of the new Grade Groups in Prostate Cancer: a multi-institutional European validation study. Prostate Cancer Prostatic Dis. 2017. PMID: 28071673. doi:10.1038/pcan.2016.66
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。